Table of Contents
Efficacy of the Combination: Meta-Analyses
Speakers for This Morning
Patient Group Comparisons
Is the Combination More Effective than Pravastatin Alone?
Event Rates for Primary Endpoints in LIPID and CARE
Accounting for Baseline Risk Factors
Meta-Analysis of these Pravastatin Secondary Prevention Trials
Trial Commonalities
Meta-Analysis Endpoints Considered
Meta-Analysis Models
Relative Risk Reduction Cox Proportional Hazards – All Trials
Relative Risk Reduction Cox Proportional Hazards – LIPID and CARE
Relative Risk Reduction Cox Proportional Hazards – LIPID and CARE
Meta-Analysis Models
Model 2 – Hierarchical, Random Effects
Model 2 – Hierarchical, Random Effects
Model 2 – Hierarchical, Random Effects
Combination is More Effective than Either Agent Alone
Model 2: Fatal or Non-Fatal MI
Meta-Analysis Models
Model 3: Fatal or Non-Fatal MI
Conclusion of Hazard Analysis over Time
PPT Slide
|